Article info
PDFTreatment
Randomised controlled trial
Extending transdermal nicotine therapy from 8 to 24 weeks increases point-prevalence abstinence at 24 but not 52 weeks
- Correspondence to Anne M Joseph
Department of Medicine, University of Minnesota, 717 Delaware Street SE, Suite 166, Minneapolis, MN 55414, USA; amjoseph{at}umn.edu
Citation
Extending transdermal nicotine therapy from 8 to 24 weeks increases point-prevalence abstinence at 24 but not 52 weeks
Publication history
- First published June 3, 2010.
Online issue publication
October 25, 2017
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions